foxo4-dri senolytic human trial
foxo4-dri senolytic human trial Peptide Cellular senescence and senolytics: the
Cellular senescence and senolytics: the path to the clinic Nature Medicine Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Tools to eliminate senescent cells Nature The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
USD26.15
USD75.15
Pay in 4 interest-free payments of $6.54 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
